Outcome of Board meeting held today, i.e 21 May 2026
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic Limited reported FY2026 standalone revenue of ₹30,068 lakhs, up 20.7% from ₹24,910 lakhs in FY2025. Profit after tax grew modestly to ₹3,406 lakhs from ₹3,344 lakhs (1.9% growth). EPS stood at ₹6.54 for FY2026. Consolidated revenue was ₹31,041 lakhs with PAT of ₹3,140 lakhs. The Board recommended a dividend of ₹0.50 per share (25% on ₹2 face value) for FY2025-26, subject to shareholder approval at the 21st AGM on 2 September 2026. Record date for dividend is 26 August 2026. The auditors issued an unmodified opinion on the financial statements. The company also appointed internal and cost auditors for FY2026-27.
The company shows healthy revenue growth of over 20% year-on-year, indicating expansion in diagnostic services. The first dividend recommendation signals cash generation and rewards shareholders. The stock could see positive reaction given the growth trajectory and dividend announcement, though the modest PAT growth (under 2%) may temper enthusiasm.